News | September 17, 2024
Wacker collaborates with MinervaX for prophylactic vaccine targeting Group B streptococcus
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
Decision on EU marketing authorisation for this population expected by September 2024
GSK and Flagship to jointly fund up to $150 million upfront
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Subscribe To Our Newsletter & Stay Updated
